| Primary |
| Cystic Fibrosis |
53.0% |
| Bronchiectasis |
17.2% |
| Pseudomonas Infection |
12.2% |
| Chronic Obstructive Pulmonary Disease |
4.7% |
| Lung Infection Pseudomonal |
1.8% |
| Asthma |
1.4% |
| Lung Disorder |
1.1% |
| Bronchitis Chronic |
0.9% |
| Pneumonia |
0.9% |
| Obstructive Airways Disorder |
0.8% |
| Gastrooesophageal Reflux Disease |
0.7% |
| Hypertension |
0.7% |
| Pneumonia Pseudomonal |
0.7% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
0.6% |
| Pain |
0.6% |
| Pseudomonas Bronchitis |
0.6% |
| Bronchitis |
0.5% |
| Cough |
0.5% |
| Pancreatic Insufficiency |
0.5% |
| Bacterial Disease Carrier |
0.4% |
|
| Death |
41.5% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
8.1% |
| Upper Respiratory Tract Infection |
7.6% |
| Pneumonia |
6.3% |
| Pseudomonas Infection |
4.6% |
| Lung Infection |
3.7% |
| Infection |
2.9% |
| Cystic Fibrosis |
2.8% |
| Dyspnoea |
2.6% |
| Lung Disorder |
2.5% |
| Pulmonary Function Test Decreased |
1.9% |
| Respiratory Failure |
1.9% |
| Staphylococcal Infection |
1.9% |
| Tinnitus |
1.8% |
| Cough |
1.7% |
| Malaise |
1.7% |
| Pyrexia |
1.7% |
| Renal Failure |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.6% |
| Weight Decreased |
1.5% |
|
| Secondary |
| Cystic Fibrosis |
28.6% |
| Pseudomonas Infection |
18.9% |
| Bronchiectasis |
14.4% |
| Chronic Obstructive Pulmonary Disease |
4.9% |
| Drug Use For Unknown Indication |
4.2% |
| Dyspnoea |
3.2% |
| Asthma |
3.0% |
| Mycobacterium Abscessus Infection |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Lung Disorder |
2.3% |
| Lung Infection Pseudomonal |
2.1% |
| Obstructive Airways Disorder |
2.1% |
| Bronchitis Chronic |
1.9% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Bronchitis |
1.3% |
| Chronic Respiratory Failure |
1.1% |
| Cough |
1.1% |
| Hypogammaglobulinaemia |
1.1% |
| Pancreatic Insufficiency |
1.1% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
0.9% |
|
| Death |
14.8% |
| Wheezing |
7.4% |
| Cough |
6.7% |
| Pseudomonas Infection |
6.0% |
| Staphylococcal Infection |
6.0% |
| Upper Respiratory Tract Infection |
6.0% |
| Red Blood Cell Sedimentation Rate Increased |
5.4% |
| Vertigo |
4.7% |
| Dyspnoea |
4.0% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
4.0% |
| Lower Limb Fracture |
4.0% |
| Lung Infection |
4.0% |
| Pyrexia |
4.0% |
| Visual Impairment |
4.0% |
| Chronic Obstructive Pulmonary Disease |
3.4% |
| Dysphonia |
3.4% |
| Tinnitus |
3.4% |
| Vomiting |
3.4% |
| Oropharyngeal Swelling |
2.7% |
| Pneumonia |
2.7% |
|
| Concomitant |
| Cystic Fibrosis |
24.7% |
| Pseudomonas Infection |
16.5% |
| Mycobacterium Abscessus Infection |
11.8% |
| Drug Use For Unknown Indication |
8.2% |
| Asthma |
6.1% |
| Gastrooesophageal Reflux Disease |
4.4% |
| Pancreatic Insufficiency |
4.0% |
| Product Used For Unknown Indication |
4.0% |
| Bronchitis |
3.8% |
| Pyrexia |
2.7% |
| Contraception |
1.5% |
| Lung Infection |
1.5% |
| Lung Infection Pseudomonal |
1.5% |
| Lung Transplant |
1.5% |
| Abdominal Pain Upper |
1.3% |
| Burkholderia Cepacia Infection |
1.3% |
| Chest Pain |
1.3% |
| Intravenous Catheter Management |
1.3% |
| Malabsorption |
1.3% |
| Medical Diet |
1.3% |
|
| Rash Macular |
13.2% |
| Tachycardia |
13.2% |
| Nephrolithiasis |
7.5% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
5.7% |
| Osteochondrosis |
5.7% |
| Pituitary-dependent Cushing's Syndrome |
5.7% |
| Renal Failure Acute |
5.7% |
| C-reactive Protein Increased |
3.8% |
| Condition Aggravated |
3.8% |
| Dehydration |
3.8% |
| Drug Ineffective |
3.8% |
| Nervous System Disorder |
3.8% |
| Neutropenia |
3.8% |
| Pulmonary Embolism |
3.8% |
| Respiratory Tract Infection |
3.8% |
| Vomiting |
3.8% |
| Wheezing |
3.8% |
| Anaphylactic Reaction |
1.9% |
| Arthralgia |
1.9% |
| Bezoar |
1.9% |
|
| Interacting |
|
|
